Polymorphs of GABA alpha 5 agonists and methods of use thereof in treatment of cognitive impairment

The present invention relates to crystalline forms of a GABAA a5 agonist, pharmaceutical compositions and combinations comprising those crystalline forms, their use in methods of treating cognitive impairment associated with central nervous system (CNS) disorders, cognitive impairment associated with brain cancer, brain cancer itself or Parkinson's disease psychosis, and methods of producing the crystalline forms. GABAAα5激动剂的结晶形式，包含那些结晶形式的药物组合物和组合，它们在治疗与中枢神经系统(CNS)障碍相关的认知损害、与脑癌相关的认知损害、脑癌本身或帕金森病精神病的方法中的用途，以及生产所述结晶形式的方法。